×

Register now for full access to all the content

First Name
Last Name
Company Name
Title
Country
Thank you for registering!
Error - something went wrong!
   

An Integrated Pharmacovigilance Model to Meet the New Regulatory Trends

August 23, 2017

Hundreds of thousand deaths caused by Adverse Drug reaction are reported yearly across the globe – and the cost to manage the effect of adverse reactions is astronomical. With that in mind, the imperative to change the pharmacovigilance model is at the forefront of Regulatory agencies agenda.

In recent years, new regulatory requirements around pharmacovigilance have been introduced in all regions. The following three trends represent a major departure from the traditional and more reactive model of pharmacovigilance:

1. A shift from a passive to active surveillance

2. A strong emphasis on risk-benefit balance

3. Globalization of pharmacovigilance

Above trends bring about several challenges and opportunities that a biopharmaceutical company need to address when building an effective pharmacovigilance system. Explore more in this white paper

Previous Flipbook
Nothing Costs More Than Failure: The Benefits of Early Commercial Strategy Development
Nothing Costs More Than Failure: The Benefits of Early Commercial Strategy Development

Learn more about Market Access Planning here!

Next Flipbook
Strengthen Your Product Value Story One Phase At A Time
Strengthen Your Product Value Story One Phase At A Time

Find out how to plan evidence generation for your value story!